Viridian Therapeutics Inc (NASDAQ:VRDN) price on Thursday, July 03, rose 2.89% above its previous day’s close as an upside momentum from buyers pushed the stock’s value to $15.67.
A look at the stock’s price movement, the close in the last trading session was $15.23, moving within a range at $14.98 and $15.94. The beta value (5-Year monthly) was 0.461. Turning to its 52-week performance, $27.20 and $9.90 were the 52-week high and 52-week low respectively. Overall, VRDN moved 8.44% over the past month.
Viridian Therapeutics Inc’s market cap currently stands at around $1.28 billion, with investors looking forward to this quarter’s earnings report slated for on 2025-May-06.
Turning to the stock’s technical picture we see that short term indicators suggest on average that VRDN is a 50% Buy. On the other hand, the stock is on average a 50% Sell as suggested by medium term indicators while long term indicators are putting the stock in 50% Sell category.
11 analyst(s) have given their forecast ratings for the stock on a scale of 1.00-5.00 for a strong buy to strong sell recommendation. A total of 1 analyst(s) rate the stock as a Hold, 10 recommend VRDN as a Buy and 0 give it an Overweight rating. Meanwhile, 0 analyst(s) rate the stock as Underweight and 0 say it is a Sell. As such, the average rating for the stock is Buy which could provide an opportunity for investors keen on increasing their holdings of the company’s stock.
VRDN’s current price about 4.59% and 11.97% off the 20-day and 50-day simple moving averages respectively. The Relative Strength Index (RSI, 14) currently prints 61.92, while 7-day volatility ratio is 6.52% and 5.37% in the 30-day chart. Further, Viridian Therapeutics Inc (VRDN) has a beta value of 0.46. Analysts have given the company’s stock an average 52-week price target of $22, forecast between a low of $13.5 and high of $45. Looking at the price targets, the low is 13.85% off current price level while to achieve the yearly target high, price needs to move -187.17%. Nonetheless, investors will most likely welcome a -40.4% jump to $22 which is the analysts’ median price.
If we refocus on Viridian Therapeutics Inc (NASDAQ:VRDN), historical trading data shows that trading volumes averaged 0.75 over the past 10 days and 868.82K over the past 3 months. The company’s latest data on shares outstanding shows there are 81.59 million shares.
The 9.78% of Viridian Therapeutics Inc’s shares are in the hands of company insiders while institutional holders own 103.44% of the company’s shares. Also important is the data on short interest which shows that short shares stood at 11.34 million on 2025-06-13, giving us a short ratio of 14.99. The data shows that as of 2025-06-13 short interest in Viridian Therapeutics Inc (VRDN) stood at 1451.0000000000002 of shares outstanding, with shares short rising to 10.55 million registered in 2025-05-15. Current price change has pushed the stock 18.62% YTD, which shows the potential for further growth is there. It is this reason that could see investor optimism for the VRDN stock continues to rise going into the next quarter.
